← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Xequel Bio, Inc.
Mt. Pleasant, SC
$24,605,010
Total funding
24
Grants
Funding over time
peak $5.2M · FY2006–24$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$18,987,501 · 16
DOD$5,617,509 · 8
By mechanism
R44$7,812,351 · 3
N01$6,620,728 · 1
—$5,617,509 · 8
R43$1,915,955 · 8
R42$1,261,212 · 1
SB1$1,000,000 · 1
Investigators at Xequel Bio, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
GRANEXIN AS A TOPICAL THERAPEUTIC TO MITIGATE CUTANEOUS RADIATION INJURY$2,657,130
N01 · FY2022 · AI
GRANEXIN AS A TOPICAL THERAPEUTIC TO MITIGATE CUTANEOUS RADIATION INJURY$2,131,855
N01 · FY2023 · AI
GRANEXIN AS A TOPICAL THERAPEUTIC TO MITIGATE CUTANEOUS RADIATION INJURY$1,693,749
N01 · FY2021 · AI
COVID-19 RESTORATION OF PULMONARY BARRIER FUNCTION IN SARS-COV-2-ASSOCIATED ACUTE RESPIRATORY DISTRESS SYNDROME$1,594,398
· FY2021 · Defense Health Agency
EVALUATION OF THE CLINICAL SAFETY OF A NOVEL PEPTIDE-BASED TOPICAL THERAPEUTIC TO PROMOTE CORNEAL REGENERATION. NEW AWARD.$1,050,000
· FY2020 · Department of the Army
Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds$999,289
R44 · FY2014 · DK
Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds$997,264
R44 · FY2016 · DK
Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds$996,533
R44 · FY2015 · DK
Improving marginal allograft outcomes through cell junction stabilization in transplantation$993,803
R44 · FY2021 · DK
Improving marginal allograft outcomes through cell junction stabilization in transplantation$987,481
R44 · FY2022 · DK
Evaluation of a Novel Connexin-Based Peptide for the Treatment of Diabetic Wounds$852,751
SB1 · FY2017 · DK
Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide$841,361
R44 · FY2018 · CA
THERAPEUTIC EYE DROP FOR THE TREATMENT OF CORNEAL INJURY AFTER CHEMICAL BURN$776,507
· FY2022 · Defense Health Agency
GRANEXIN TO PREVENT INJURY PROGRESSION AND OPTIMIZE HEALING OUTCOME OF ACUTE BURNS$749,820
· FY2016 · Department of the Army
GRANEXIN GEL TO IMPROVE BURN WOUND HEALING$675,493
· FY2020 · Defense Health Agency
Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide$655,532
R44 · FY2019 · CA
Restoration of Skin Structure and Function Post-Wounding$631,997
R42 · FY2010 · AR
Restoration of Skin Structure and Function Post-Wounding$629,215
R42 · FY2009 · AR
EVALUATION OF AN INNOVATIVE THERAPEUTIC TO PREVENT AND/OR DELAY THE PROGRESSION OF ALI/ARDS IN A NON-HUMAN PRIMATE MODEL$475,391
· FY2022 · Defense Health Agency
Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds$323,674
R44 · FY2011 · DK